Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach

Author:

Carton LouiseORCID,Niot Candice,Kyheng Maéva,Petrault Maud,Laloux Charlotte,Potey Camille,Lenski MarieORCID,Bordet Régis,Deguil Julie

Abstract

AbstractSeveral observational studies have found a link between the long-term use of benzodiazepines and dementia, which remains controversial. Our study was designed to assess (i) whether the long-term use of benzodiazepines, at two different doses, has an irreversible effect on cognition, (ii) and whether there is an age-dependent effect. One hundred and five C57Bl/6 male mice were randomly assigned to the 15 mg/kg/day, the 30 mg/kg/day diazepam-supplemented pellets, or the control group. Each group comprised mice aged 6 or 12 months at the beginning of the experiments and treated for 16 weeks. Two sessions of behavioral assessment were conducted: after 8 weeks of treatment and after treatment completion following a 1-week wash-out period. The mid-treatment test battery included the elevated plus maze test, the Y maze spontaneous alternation test, and the open field test. The post-treatment battery was upgraded with three additional tests: the novel object recognition task, the Barnes maze test, and the touchscreen-based paired-associated learning task. At mid-treatment, working memory was impaired in the 15 mg/kg diazepam group compared to the control group (p = 0.005). No age effect was evidenced. The post-treatment assessment of cognitive functions (working memory, visual recognition memory, spatial reference learning and memory, and visuospatial memory) did not significantly differ between groups. Despite a cognitive impact during treatment, the lack of cognitive impairment after long-term treatment discontinuation suggests that benzodiazepines alone do not cause irreversible deleterious effects on cognitive functions and supports the interest of discontinuation in chronically treated patients.

Publisher

Springer Science and Business Media LLC

Subject

Biological Psychiatry,Cellular and Molecular Neuroscience,Psychiatry and Mental health

Reference56 articles.

1. Bordet R, Carton L, Deguil J, Dondaine T. Neuropsychopharmacologie. 2019. https://www.elsevier-masson.fr/neuropsychopharmacologie-9782294752995.html#mp-ajax-all-reviews. Accessed Jan 2021.

2. López-Pelayo H, Coma A, Gual A, Zara C, Lligoña A. Call for action: benzodiazepine prescription prevalence analysis shows off-label prescription in one in eleven citizens. Eur Addict Res. 2019;25:320–9.

3. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72:136–42.

4. Bénard-Laribière A, Pariente A. [Benzodiazepine use and misuse in France]. Presse Med. 2018;47:878–81.

5. Agence nationale de sécurité du médicament et des produits de santé. Etat des lieux de la consommation des benzodiazépines en France. 2017. https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Etat-des-lieux-de-la-consommation-des-benzodiazepines-Point-d-Information. Accessed Jan 2021.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3